Alpha Tau Medical (DRTS) Stock Price, News & Analysis

Company Overview

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area. The company has evaluated the technology in clinical studies involving several types of solid tumors, including skin, head and neck, oral, breast, pancreatic and other cancers. Alpha DaRT remains an investigational treatment in the jurisdictions where it is being studied, and regulatory status may vary by geography.

Founded in 2016, Alpha Tau Medical is headquartered in Tel Aviv, Israel, and has conducted research and clinical development activities in Israel, the United States and other international markets. The company was co-founded by Uzi Soffer, who has served as its chief executive officer, alongside researchers and physicians involved in the development of the Alpha DaRT platform.

Key Stats

• Today's Range: $13.65 to $14.25
• 50-Day Range: $12.99 to $15.50
• 52-Week Range: $3.43 to $15.79
• Volume: 484,624 shs
• Average Volume: 471,065 shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.40
• Consensus Rating: Hold

Alpha Tau Medical Stock Analysis - MarketRank™

Alpha Tau Medical scored higher than 45% of companies evaluated by MarketBeat, and ranked 728th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Alpha Tau Medical has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Alpha Tau Medical has a consensus price target of $15.40, representing about 12.1% upside from its current price of $13.74.

Amount of Analyst Coverage

Alpha Tau Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Tau Medical are expected to grow in the coming year, from ($1.05) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Tau Medical is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Tau Medical is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Tau Medical has a P/B Ratio of 15.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.31% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 6.63.

Change versus previous month

Short interest in Alpha Tau Medical has recently decreased by 1.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Tau Medical does not currently pay a dividend.

Dividend Growth

Alpha Tau Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.91

News Sentiment

Alpha Tau Medical has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Alpha Tau Medical this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for DRTS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

2 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alpha Tau Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $291,285.00 in company stock.

Percentage Held by Insiders

39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.65% of the stock of Alpha Tau Medical is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DRTS
• CIK: 1871321
• Web: www.alphatau.com
• Phone: 972-3577-4115
• Fax: N/A
• Employees: 121
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Alpha Tau Medical: $15.40
• High Price Target: $30.00
• Low Price Target: $8.00
• Potential Upside/Downside: +12.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -138.12%
• Return on Assets: -81.68%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 11.09
• Quick Ratio: 7.79

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 15.61

Miscellaneous

• Outstanding Shares: 90,330,000
• Free Float: 54,647,000
• Market Cap: $1.24 billion
• Optionable: No Data
• Beta: 1.22